Remibrutinib NEW
| Price | $98 | $233 | $378 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: Remibrutinib | CAS No.: 1787294-07-8 |
| Purity: 99.74% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | Remibrutinib |
| Description | Remibrutinib (Rhapsido) belongs to small molecule inhibitors and is a highly selective, covalent Bruton's tyrosine kinase (BTK) inhibitor (IC50 = 1 nM) with oral activity and cell permeability. The IC50 for inhibiting BTK activity in blood is 0.23 μM. This compound can be used in research on chronic urticaria. |
| In vitro | Methods: Heparinized whole blood was collected and treated with Remibrutinib, then incubated with anti-IgE at 37°C and 5% CO? for 25 minutes. A basophil activation test was performed using flow cytometry to detect the proportion of CD63+ and CD203c+ basophils. Results: Remibrutinib inhibited CD63 expression in a dose-dependent manner, with efficacy observed at a single 5 mg dose and near-complete inhibition achieved at ≥100 mg. The maximum inhibition rate of CD203c reached 84%, demonstrating potent in vitro inhibitory activity against basophil activation. [1] Methods: Hirudin/citrate-anticoagulated human whole blood was collected and co-incubated with Remibrutinib at concentrations of 0.03–0.5 μM at 37°C for 1 hour. Platelet aggregation and in vitro bleeding time were assessed using multi-electrode aggregometry and the Platelet Function Analyzer-200. Results: Remibrutinib inhibited GPVI-mediated platelet aggregation in a dose-dependent manner, with an IC?? of 0.03 μM. At 0.1 μM, inhibition of the Btk-dependent pathway exceeded 90%, with significantly less impact on hemostatic function compared to rilzabrutinib. [2] |
| In vivo | Methods:: Using experimental autoimmune encephalomyelitis mice expressing human/rat myelin oligodendrocyte glycoprotein as a model, Remibrutinib was suspended in 0.5% methylcellulose + 0.5% Tween 80 aqueous solution and administered by gavage from the day of immunization at doses of 3/30 mg/kg twice daily until the end of the experiment. Results: Remibrutinib improved neurological symptoms in a dose-dependent manner, with 30 mg/kg significantly inhibiting disease progression without depleting B cells or reducing total immunoglobulin levels.[3] |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.85 mM), Sonication is recommended. DMSO : 240 mg/mL (472.88 mM), Sonication is recommended. |
| Keywords | Remibrutinib | Inhibitor | inhibit | Btk | Bruton tyrosine kinase |
| Inhibitors Related | evobrutinib | (±)-Zanubrutinib | CP-547632 | CHMFL-EGFR-202 | Sunvozertinib | Ibrutinib | IBT6A | Orelabrutinib | Atuzabrutinib | Tyrosinase-IN-16 | Rilzabrutinib | Birelentinib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-03 | ||
|
VIP7Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2025-12-15 | ||
|
VIP5Y
|
Shanghai Joiny Pharmaceutical Co.,LTD
|
2025-11-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY